Filing Flows › Biomerica (BMRA) › Q3 FY26
Biomerica (BMRA) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Apr 13, 2026
Biomerica (BMRA) reported revenue of $987K for the third quarter fiscal 2026 (Q3 FY26), -12% from a year earlier and -18% from the quarter before. Operating margin was -131.5%, net loss $1.3M (132.9% of revenue).
Biomerica, Q3 FY26: revenue $987K (-12% year over year), operating margin -131.5%, net loss $1.3M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $987K | -18% | -12% |
| Operating profit | −$1.3M | — | — |
| Net earnings | −$1.3M | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $1.0M in Q3 FY26, down 12% year over year and down 18% from the previous quarter. Clinical Lab was the largest line at 63% of revenue. Contract Manufacturing lost $153K year over year (down 48%), 116% of the total change.
Operating costs exceeded revenue by $1.3M, an operating margin of -131.5%. The fastest-growing cost line was Sales & marketing (+27%). The quarter ended with a net loss of $1.3M, narrower than the previous quarter's $1.3M loss.
Operating cash flow was −$1.2M. Non-cash charges added back $20K of depreciation and amortization and $135K of share-based compensation. Working capital and other items used $93K.
Questions
What was Biomerica's revenue in the third quarter fiscal 2026?
Biomerica (BMRA) reported revenue of $987K for the third quarter fiscal 2026 (Q3 FY26), -12% from a year earlier and -18% from the quarter before.
Was Biomerica profitable in the third quarter fiscal 2026?
Operating loss was $1.3M (-131.5% of revenue) and net loss $1.3M.
Source: Biomerica 10-Q on SEC EDGAR.